ReviewPLoS pathogens2025
The neonatal Fc receptor (FcRn): Guardian or Trojan Horse in viral infection?
Review in PLoS pathogens, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- A Humanized Anti-gD Broadly Neutralizing Antibody Confers Complete Post-Exposure Protection Against Pseudorabies Virus.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- A mouse model of Zika virus sexual transmission reveals a limited transmission window shorter than viral RNA persistence in semen.PLoS pathogens · 2026Article
- Functional Antibody-Dependent Enhancement as an Immune Assessment Platform: Development, Standardization, and Translational Interpretation in Flavivirus Research.Pathogens (Basel, Switzerland) · 2026Review
- From molecular mechanisms of glycosphingolipid function to bio-therapeutic applications.Cellular and molecular life sciences : CMLS · 2026Review
- Prolonged neonatal phosphate retention and transient hypercalcemia following antenatal Burosumab exposure: a pharmacovigilance alert.Therapeutic advances in drug safety · 2026Article
- Development and characterization of a monoclonal antibody against Pseudorabies virus glycoprotein B and its application in tracking viral infection.Frontiers in microbiology · 2026Article
- A glycoprotein D-targeted lipid nanoparticle-encapsulated mRNA vaccine elicits strong protective immunity against pseudorabies virus.Journal of virology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The neonatal Fc receptor (FcRn), well-known for mediating the transfer of maternal immunoglobulin G (IgG) to neonates, plays a critical role in neonatal antimicrobial defenses. Furthermore, FcRn regulates IgG and albumin homeostasis via pH-dependent recycling pathways, thereby prolonging their plasma half-life in circulation. FcRn also enables bidirectional transcytosis of antibodies across cellular barriers, a function essential for maintaining humoral immunity. However, recent studies have demonstrated that some viruses exploit FcRn to facilitate viral infection, underscoring its dual role in the viral lifecycle. This review aims to comprehensively discuss the dual functions of FcRn during viral infections, with particular focus on how diverse viruses utilize FcRn to promote infection. Here, we summarize the molecular mechanisms underlying FcRn-mediated proviral processes, including viral uncoating, transcytosis, and antibody-dependent enhancement (ADE) of infection. Finally, we propose potential therapeutic strategies targeting FcRn to inhibit viral replication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.